Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Intuitive Surgical Inc.
ISRGHealthcareGenerated Jul 5, 2026, 08:12 PM UTC
ISRG (Intuitive Surgical Inc.) analytical snapshot. Revenue grew +14.5% YoY to $7.12B. Net margin at 25.24% (expanding ▲). Return on equity 10.94%, ROA 9.59%, ROIC 10.75%. Market cap $150.88B at $426.01 per share. Trailing P/E 84.69, P/S 21.18, P/B 8.63. EV/Operating income ≈ 84.26 (EV $148.87B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score -1 (data confidence 74%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFundamentals
Revenue grew +14.5% YoY to $7.12B. Net margin at 25.24% (expanding ▲). Return on equity 10.94%, ROA 9.59%, ROIC 10.75%.
- Revenue grew +14.5% YoY to $7.12B.
- Net margin at 25.24% (expanding ▲).
- Return on equity 10.94%, ROA 9.59%, ROIC 10.75%.
- Gross margin 66.39%, operating margin 24.80%.
- Net income up ▲ +36.0% YoY.
- Asset turnover 0.35 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | — | 11.96 |
| 2017 | — | — | — | — | — | — | 10.19 |
| 2018 | $2.71B | — | 69.94 | 35.09 | 27.28 | — | 15.45 |
| 2019 | $3.14B | +16.0% | 70.17 | 33.87 | 21.38 | — | 10.05 |
| 2020 | $3.72B | +18.7% | 69.92 | 32.21 | 30.29 | — | 13.65 |
| 2021 | $4.48B | +20.3% | 69.45 | 30.69 | 30.80 | — | 14.17 |
| 2022 | $4.36B | -2.7% | 65.65 | 24.09 | 24.33 | — | 8.91 |
| 2023 | $5.71B | +31.0% | 69.32 | 31.89 | 29.85 | — | 15.44 |
| 2024 | $6.22B | +9.0% | 67.44 | 25.35 | 21.25 | — | 9.94 |
| 2025 | $7.12B | +14.5% | 66.39 | 24.80 | 25.24 | — | 10.94 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $2.25B | +19.2% | — | 30.99% |
| Jun 30, 2025 | $4.69B | +20.3% | +108.3% | 28.91% |
| Jun 30, 2025 | $2.44B | -37.4% | -48.0% | 55.61% |
| Sep 30, 2025 | $7.20B | +21.2% | +195.0% | 28.63% |
| Sep 30, 2025 | $2.51B | -57.8% | -65.2% | 82.28% |
| Mar 31, 2026 | $2.77B | +23.0% | +10.6% | 29.65% |
Filings & Ownership
Latest annual report (10-K) filed Feb 3, 2026. Latest quarterly report (10-Q) filed Apr 22, 2026. 7 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 3, 2026.
- Latest quarterly report (10-Q) filed Apr 22, 2026.
- 7 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Intuitive Surgical Inc.; broad institutional reporting.
- Recent filers include Saranac Partners Ltd, COATUE MANAGEMENT LLC, COATUE MANAGEMENT LLC.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| Saranac Partners Ltd | 13F-HR | Dec 5, 2025 |
| COATUE MANAGEMENT LLC | 13F-HR | Aug 14, 2025 |
| COATUE MANAGEMENT LLC | 13F-HR | Nov 14, 2025 |
| COATUE MANAGEMENT LLC | 13F-HR | May 15, 2025 |
| COATUE MANAGEMENT LLC | 13F-HR | May 15, 2026 |
| Date | Form | Description |
|---|---|---|
| May 28, 2026 | 8-K | 8-K |
| May 4, 2026 | 8-K | 8-K |
| Apr 21, 2026 | 8-K | 8-K |
| Mar 2, 2026 | 8-K | 8-K |
| Jan 22, 2026 | 8-K | 8-K |
| Jan 14, 2026 | 8-K | 8-K |
| Dec 18, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
No significant implicit signals detected. Key metrics are changing within normal ranges.
- Endogenous analysis: No significant implicit signals detected in the latest filing. Key metrics are changing within normal ranges — the filing appears consistent with prior-period patterns.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $6.22B | $7.12B | $901.9M | +14.5% |
| Gross profit | $4.20B | $4.73B | $533.5M | +12.7% |
| Operating income | $1.58B | $1.77B | $189.7M | +12.0% |
| Net income | $1.32B | $1.80B | $475.7M | +36.0% |
| Operating cash flow | $1.49B | $1.81B | $323.0M | +21.7% |
| Total assets | $15.44B | $18.74B | $3.30B | +21.4% |
| Total liabilities | $2.04B | $2.21B | $169.4M | +8.3% |
| Cash & equivalents | $2.75B | $2.03B | $-722.7M | -26.3% |
| Stockholders equity | $13.31B | $16.43B | $3.13B | +23.5% |
| Inventory | $1.22B | $1.49B | $266.6M | +21.8% |
| Accounts receivable | $1.13B | $1.23B | $95.2M | +8.4% |
| R&D expense | $879.0M | $998.8M | $119.8M | +13.6% |
| SG&A expense | $1.74B | $1.96B | $224.0M | +12.9% |
| Type | Concepts |
|---|---|
| Added | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets, BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue, ProceedsFromSaleOfOtherProductiveAssets, ShareRepurchaseProgramExciseTax |
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AcquisitionCosts, AllowanceForDoubtfulAccountsReceivableCurrent, BuildingsAndImprovementsGross, BusinessCombinationContingentConsiderationLiabilityCurrent, CapitalizedComputerSoftwareGross, CapitalizedContractCostAmortization, ConstructionInProgressGross, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
Unlock the rest
- ProValuationMarket cap $150.88B at $426.01 per share.
- ProPrice & TechnicalsPrice $426.01 — downtrend (below 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Low.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -1
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Intuitive Surgical Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+14.5%** YoY to $7.12B..
Peer comparison
Defensive groupHow ISRG stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Intuitive Surgical Inc. ISRG● you | -1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |